Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
medicalxpress - New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
AI Summary: New analyses show that older patients with chronic kidney disease still gain meaningful benefit from SGLT2 inhibitors — despite age-related skepticism — while linked studies report rises in hemoglobin and shifts in iron/erythropoiesis markers. Clinicians should not reflexively withhold SGLT2s for advanced age and should monitor hematologic indices.
Related Stories
Stem cells show potent promise as a diabetes treatment / 5 months
FDA clears first once‑weekly basal insulin for Type 2 diabetes / 6 months
Cardiology mourns Eugene Braunwald’s death at 96 / 5 months
First-in-human trial primes immune system to accept donor livers / 6 months
ESMO issues new metastatic colorectal cancer clinical guideline / 6 months
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 6 months
Studies link GLP‑1 weight‑loss drugs to increased hair loss risk / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Drug Pricing, Supply Chain, Hospital Operations, Reproductive Health and look for the RSS link.
StackHealth Time Machine